Although UA itself might not be sufficient for specific VRK1 inhibition in vivo, employing de novo structure-based drug design methods or fragment-based approaches at the interacting residues with UA or exploiting structural analogs of UA could facilitate development of novel drugs for the treatment of lung cancer, with minimal side effects. This evidence concerns the gene VRK1 and lung cancer.